Scribe Therapeutics
Scribe Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Alameda, California, engineering CRISPR-based genetic medicines through its proprietary "CRISPR by Design" platform. Co-founded by molecular engineers Benjamin Oakes, Brett Staahl, and David Savage alongside CRISPR co-inventor Jennifer Doudna, the company builds highly engineered CasX-derived enzymes — including its X-Editing (XE) molecules for precise gene editing and ELXR epigenetic long-term X-repressor technology for durable gene silencing without altering the underlying DNA sequence. Scribe focuses initially on cardiometabolic disease, the leading cause of death globally, and expands into areas such as sickle cell disease and neurological conditions through strategic pharmaceutical partnerships. The company is backed by a16z and Menlo Ventures and was surfaced to the API Evangelist network as a venture portfolio company. Scribe Therapeutics is a therapeutics and drug-discovery company and does not currently publish a public developer API, SDK, or documented API surface.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Scribe Therapeutics the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Scribe Therapeutics scores 11.9/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Scribe Therapeutics
Each block below is one kind of artifact we hold for Scribe Therapeutics. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Scribe Therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 6
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/scribe-therapeutics · machine-readable index on apis.io